Seralutinib Will Succeed As Aging Populations Drive PAH Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$15.00
86.7% undervalued intrinsic discount16 Aug
US$1.99
1Y
113.2%7D
14.7%